• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    3 Promising Penny Stocks With Market Caps Under $400M

    Simply Wall St·06/27/2025 11:05:05
    Listen to the news

    The market is up 2.7% over the last week and has climbed 13% in the past year, with earnings expected to grow by 15% per annum in the coming years. The term 'penny stocks' might feel like a relic of past market eras, but these smaller or relatively new companies can offer affordability and growth potential when paired with strong financials. In this article, we explore three penny stocks that stand out for their financial strength amidst current market conditions.

    Top 10 Penny Stocks In The United States

    Name Share Price Market Cap Rewards & Risks
    Waterdrop (WDH) $1.35 $488.24M ✅ 4 ⚠️ 0 View Analysis >
    WM Technology (MAPS) $0.9265 $148M ✅ 4 ⚠️ 1 View Analysis >
    Tuniu (TOUR) $0.9326 $95.14M ✅ 3 ⚠️ 2 View Analysis >
    Safe Bulkers (SB) $3.66 $376.5M ✅ 3 ⚠️ 3 View Analysis >
    Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ✅ 2 ⚠️ 5 View Analysis >
    Flexible Solutions International (FSI) $4.50 $55.08M ✅ 1 ⚠️ 2 View Analysis >
    BAB (BABB) $0.8339 $6.1M ✅ 2 ⚠️ 3 View Analysis >
    Lifetime Brands (LCUT) $3.77 $86.97M ✅ 3 ⚠️ 2 View Analysis >
    Marine Petroleum Trust (MARP.S) $4.43 $8.76M ✅ 1 ⚠️ 4 View Analysis >
    TETRA Technologies (TTI) $3.46 $441.8M ✅ 4 ⚠️ 3 View Analysis >

    Click here to see the full list of 450 stocks from our US Penny Stocks screener.

    Let's uncover some gems from our specialized screener.

    Vanda Pharmaceuticals (VNDA)

    Simply Wall St Financial Health Rating: ★★★★★★

    Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for high unmet medical needs globally, with a market cap of approximately $271.69 million.

    Operations: The company generates its revenue primarily from its Biotechnology (Startups) segment, which accounted for $201.35 million.

    Market Cap: $271.69M

    Vanda Pharmaceuticals, with a market cap of approximately US$271.69 million, is navigating the challenging landscape of penny stocks by focusing on innovative treatments for rare diseases and psychiatric conditions. Despite being unprofitable with increasing losses over the past five years, Vanda's financial stability is supported by its debt-free status and strong asset position relative to liabilities. Recent developments include the initiation of a clinical trial for a rare neuromuscular disorder treatment and FDA progress on Bysanti, an antipsychotic drug potentially offering long-term exclusivity if approved. Revenue guidance remains optimistic at US$210-250 million for 2025 despite recent net loss increases.

    VNDA Revenue & Expenses Breakdown as at Jun 2025
    VNDA Revenue & Expenses Breakdown as at Jun 2025

    ChargePoint Holdings (CHPT)

    Simply Wall St Financial Health Rating: ★★★★☆☆

    Overview: ChargePoint Holdings, Inc., along with its subsidiaries, operates electric vehicle charging networks and solutions across North America and Europe, with a market cap of approximately $0.33 billion.

    Operations: The company's revenue is primarily derived from its electric equipment segment, totaling $407.68 million.

    Market Cap: $330.86M

    ChargePoint Holdings, with a market cap of US$0.33 billion, is navigating the penny stock landscape by expanding its EV charging network across North America and Europe. Despite being unprofitable and experiencing increased losses over the past five years, the company's financial position shows short-term assets exceeding liabilities and a substantial cash runway. Recent collaborations with Eaton aim to streamline EV infrastructure deployment, enhancing ChargePoint's strategic role in the ecosystem. However, high net debt levels and significant insider selling present challenges. Revenue guidance for Q2 2025 indicates potential stabilization between US$90 million to US$100 million amidst ongoing volatility.

    CHPT Revenue & Expenses Breakdown as at Jun 2025
    CHPT Revenue & Expenses Breakdown as at Jun 2025

    Verde Resources (VRDR)

    Simply Wall St Financial Health Rating: ★★★★☆☆

    Overview: Verde Resources, Inc. operates through its subsidiaries in the production of biochar derived from waste materials in the dairy, palm, and other natural resource industries across the United States and Malaysia, with a market cap of $115.83 million.

    Operations: The company's revenue is generated from the production of biochar in the United States and Malaysia, focusing on waste materials from industries such as dairy and palm.

    Market Cap: $115.83M

    Verde Resources, with a market cap of US$115.83 million, is pre-revenue and faces challenges typical of penny stocks, such as high volatility and limited cash runway. Despite these hurdles, the company is making strides in sustainable infrastructure through a 10-year partnership with C-Tw twelve Pty Ltd., focusing on low carbon asphalt technology. This collaboration has led to the issuance of biochar-based Carbon Removal Credits, marking an innovative step in climate solutions. Recent executive changes bring experienced leadership to navigate expansion and regulatory compliance as Verde aims for commercialization success amidst financial constraints.

    VRDR Debt to Equity History and Analysis as at Jun 2025
    VRDR Debt to Equity History and Analysis as at Jun 2025

    Seize The Opportunity

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.